Mitomicin Accord (Mitomycin)

Mitomycin is an alkylating agent that is reduced inside cancer cells to generate reactive species. These species create cross‑links between DNA strands, preventing DNA replication and transcription, which leads to cell cycle arrest and apoptosis of rapidly dividing tumour cells.

The dosage of Mitomicin Accord is individualized by the prescribing oncologist based on the specific cancer type, stage, patient weight, renal function and treatment protocol. Only a qualified healthcare professional should determine the appropriate dose and schedule.

Mitomicin Accord is classified as contraindicated in pregnancy because it can cause fetal harm. It is also not recommended for breastfeeding mothers, as it may be excreted in milk and affect the infant. Women of child‑bearing potential should use effective contraception during treatment.

To order Mitomicin Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Compared with other alkylating agents, mitomycin offers a distinct mechanism of DNA cross‑linking and is particularly effective in certain solid tumours such as bladder and gastric cancer. Its toxicity profile differs, with notable risks of pulmonary fibrosis and renal effects, requiring specific monitoring that may not be needed with some alternatives.

Mitomicin Accord should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the product. Before administration, it must be reconstituted under aseptic conditions according to the manufacturer’s instructions.

Mitomicin Accord is given by intravenous infusion, typically over a period of 30‑60 minutes, depending on the prescribed protocol. Administration is performed in a clinical setting by qualified healthcare personnel, with monitoring for infusion‑related reactions.

The most serious risks include severe myelosuppression leading to infection or bleeding, pulmonary fibrosis that can impair breathing, renal toxicity affecting kidney function, and rare but life‑threatening anaphylactic reactions. Patients should be closely monitored for these complications throughout treatment.

Mitomicin Accord should not be used in individuals with known hypersensitivity to mitomycin, in pregnant or breastfeeding women, and in patients with severe renal impairment or uncontrolled infections. It is also contraindicated in patients receiving certain strong CYP450 inducers that could markedly reduce its efficacy.